OHSU funds projects to provide culturally relevant resources, education, workshops for people across Oregon.

As the only center in the Pacific Northwest, OHSU will collaborate with other selected centers to address unmet needs in cancer therapy.

OHSU Knight Cancer Institute director, employees share their appreciation in a thank-you video.

NIH-backed projects will help accelerate the use of artificial intelligence, machine learning to tackle complex research challenges for cancer, other diseases.

National study found that patients sought care at later stages of melanoma skin cancer, leading to potentially worse outcomes.

Newly funded projects will focus on needs of Spanish-speaking communities, measure impact of financial support during cancer treatment, provide youth peer education for HPV prevention.

OHSU experts welcome the spring season with advice on using sunscreen, sun-protective clothing, how to perform skin checks.

The OHSU Knight Cancer Institute is among top sites for enrolling subjects in international clinical trial.

Funding will support therapeutic advances, increase services for high-risk patients, fuel expansion in early cancer detection.

New study co-led by OHSU researchers provides most robust U.S. estimate to date, shows overdiagnosis not as ‘alarmingly frequent’ as commonly believed.

Institute leaders helped shape revamped plans, say OHSU will be ‘instrumental’ in contributing to the cause moving forward.

Projects aim to prevent lung cancer, increase awareness around risk for pancreatic cancer, provide resources to patients with cancer in rural Oregon.

Family with ‘so many touchpoints’ to OHSU travels from Seattle for pancreatic cancer surgery.

OHSU patient is second in the U.S. to use a new treatment for a rare form of cancer, defies odds with positive response.

OHSU will join the company’s global precision oncology network, enhance real-time information, knowledge sharing to benefit patients.

Community Partnership Program funding will support food insecurity, COVID-19 outreach, technology to promote social distancing guidelines, more.

OHSU’s Dr. Brian Druker: ‘The Knights’ incredible generosity leaves an indelible legacy in the world of cancer research.’

Oncology experts will head the Division of Hematology and Medical Oncology, direct new center for experimental therapeutics.

Real-time study will conduct targeted statewide COVID-19 testing, precision mapping to help safely ease physical distancing, control future outbreaks.

OHSU melanoma expert describes how to protect your skin from sun damage, prevent skin cancer while staying home.

See’s Candies lift the spirits of patients and front-line health care workers.

Donation supports new Oregon-based collaboration utilizing “big data” to better fight cancer and other diseases.

OHSU tapped to join new early detection study; men and women aged 50 and older may be eligible to participate.

Collaboration aims to expedite discoveries for patients with leukemia.

OHSU patient began treatment with a tumor more than 15 inches in length.

OHSU Knight Cancer Institute’s Community Partnership Program has invested more than $3 million in nearly 120 projects since 2014.

OHSU researchers lend expertise to six distinct publications on improved cancer prevention activities.

As a member of the OHSU Knight Cancer Network, Saint Alphonsus will help expand cancer research, clinical trial opportunities, advanced specialized care to patients.

New center of excellence aims to improve rates of cervical cancer screening, tobacco cessation.

Together with collaborators in the U.S. and U.K., the OHSU Knight Cancer Institute launches new alliance solely focused on the early detection of cancer.

Newly funded projects in Hood River, Wasco, Crook, Benton, Multnomah counties to raise awareness of cancer prevention through HPV vaccination.

Teen hopes donation will raise awareness for early detection research and support of treatment initiatives.

The collaboration will develop large data analyzation approaches to quickly identify cell abnormalities that lead to cancer and other diseases.

May 18 event will mark the launch of a statewide public awareness campaign to help educate the public about the importance of skin cancer screening, early detection.

Research Week 2019: M.D./Ph.D. student's experience translating for his family fuels his desire to treat underserved communities.

OHSU’s Center for Health & Healing Building 2 and the Gary & Christine Rood Family Pavilion offer an innovative approach to patient and family experience.

By acquiring OHSU's MolecularMD, the clinical research organization ICON, based in Dublin, Ireland, has expanded its laboratory offering in molecular diagnostic testing and brings expanded testing platforms.

Awarded by the Royal Swedish Academy of Sciences, the Sjöberg Prize recognizes scientists who have made major discoveries in cancer research.

Newly funded projects include the Asian Health & Service Center, which received a grant to help increase culturally and linguistically appropriate cancer resources for Asian communities in Oregon.

OHSU physician-researcher presents updated gene transfer therapy data at conference, publishes study results in The New England Journal of Medicine.

A study involving hundreds of patient samples may reveal new treatment options for patients facing an aggressive form of leukemia.

State-of-the-art cancer research facility will support a collaborative atmosphere, bring multidisciplinary scientists together under one roof.

New research finds patient care focused on relieving symptoms, stress reduces suicide risk by 81 percent.

Gene transfer therapy, Kymriah, now available for adults with a common form of lymphoma.

Via a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.

Druker is recognized for his groundbreaking research in treating patients with leukemia.

Annual community event will offer free skin cancer exams, samples and services from skin care professionals, and a 5K Walk or Fun Run to benefit melanoma research.

A new clinical trial offers alternatives.

OHSU oncologist studies how race, gender, health insurance status impacts access among vulnerable populations with cancer.

Local family funds prestigious award to enable innovative studies, mentor the next generation of physician-scientists.

Knight Cancer Institute associate director for basic research reflects on building labs, challenging dogma, and dedicating her life to impacting cancer research.

OHSU’s 320,000 square foot cancer research building is taking shape, with completion slated for late summer 2018.

Apalutamide significantly delayed the onset of symptoms, metastasis or death in Phase III clinical trial.

OHSU research team discovers a tumor’s ‘microenvironment’ plays a critical role in how a common type of breast cancer responds to treatment.

Pacific Northwest National Laboratory and OHSU today announced a joint collaboration to improve patient care by focusing research on highly complex sets of biomedical data, and the tools to interpret them.

Grants support community-based cancer prevention, screening and survivorship programs in every Oregon county.

Patients say exercise video is helpful at all stages of diagnosis and recovery.

OHSU is the first in the nation to implement a virtual simulation tool into its clinical care program, allowing patients to see, hear and understand what treatment will be like.

Early results from the BLU-285 study demonstrate efficacy for patients with gastrointestinal stromal tumors.

The Kuni Foundation's award will support new research in the field of prostate cancer.

One of the most highly cited medical scientists in the world, Mills brings a breadth of research, leadership experience to OHSU.

The first FDA-approved gene transfer therapy for patients with acute lymphoblastic leukemia will be available at a handful of approved hospitals, including OHSU Doernbecher.

A new study focused on the research and development spending of some pharmaceutical companies found the cost of bringing a cancer drug to market was significantly less than previously reported.

OHSU will collaborate with other other teams to establish a pediatric cancer and rare disease data program--a first for the pediatric research community.

OHSU Knight Cancer Institute has been awarded the National Cancer Institute’s, NCI, premier status: Comprehensive Cancer Center.

The Office of Cancer Clinical Proteomics Research (OCCPR) at the National Cancer Institute (NCI) announced the institutes that will comprise the Proteogenomic Translational Research Centers, a group created to collaborate with NCI-sponsored clinical trials.

Today the OHSU Knight Cancer Institute announced that internationally renowned bioengineering and technology expert Mike Heller, Ph.D., will join the institute’s Cancer Early Detection Advanced Research Center, or CEDAR, to lead its technology efforts.

A study of more than 500 cancer survivors found that many years after completing treatment, nearly half of women cancer survivors continued to experience chemotherapy-induced peripheral neuropathy, CIPN.

“Despite everything I’ve been through, in some ways, I’m in the best shape of my life now, as a cancer survivor,” says Joe Heiden, a competitor on the television program "American Ninja Warrior."

The Community Partnership Program will fund cancer-related projects in every county in Oregon.

The National Cancer Institute has awarded a research team at the OHSU Knight Cancer Institute $9.2 million over five years to serve as a Research Center in the NCI’s Cancer Systems Biology Consortium, or CSBC.

May is Melanoma Awareness Month, and the OHSU Knight Cancer Institute will again hold the “War on Skin Cancer Event” Saturday, May 20, from 9 a.m. to 2 p.m., to educate the community about sun safety and skin cancer risk factors.

Kerri Winters-Stone, Ph.D., researches the use of physical activity to prevent and manage chronic disease. Her studies have shown that cancer survivors can benefit from exercise that reverses treatment-related side effects and symptoms.

Stephen Lloyd's recent research, published in the Proceedings of the National Academy of Sciences, drew upon his expertise as a cancer biologist and focused on a global health problem affecting hundreds of thousands of individuals in Southeast Asia and Sub-Saharan Africa, where a specific class of toxic compounds, called aflatoxins, are commonly found in food sources.

A free War on Skin Cancer Event at OHSU gives attendees the chance to talk with experts, participate in fundraising, evaluate potential risk for melanoma, and more.

There’s an urgency in Anupriya Agarwal’s voice when she talks about her acute myeloid leukemia research: “We need to do something beyond what we’ve already done,” she said. “The treatment hasn’t changed in decades, and that can’t be our only answer.”

Vinay Prasad, M.D., M.P.H., has been awarded a $2 million grant to support an effort to uncover treatments and tests that are contradicted by reliable evidence. The three-year project calls for sharing the findings via a public website and developing teaching modules that can be incorporated into medical school or residency curricula.

The New England Journal of Medicine published results from a nearly 11-year follow-up study, that showed an estimated overall survival rate of 83.3 percent. According to the National Cancer Institute, prior to Gleevec’s 2001 FDA approval, fewer than 1 in 3 CML patients survived five years past diagnosis.

The OHSU Knight Cancer Institute and Legacy Health have signed business agreements with The Vancouver Clinic, or TVC, to expand their network of integrated adult cancer care clinics to southwest Washington. The agreement is the latest addition to the OHSU Knight-Legacy Health Cancer Collaborative, established in 2013.

Research published today in the journal Oncotarget, sought to better understand one “typo” in a standard leukemia assay, or test. While studying cancer biology and completing his doctorate at the OHSU Knight Cancer Institute, Kevin Watanabe-Smith, Ph.D., encountered a new problem: an issue with the model system itself.

Commenting on recent research findings from a team at Stanford University, Sancy Leachman, M.D., Ph.D., director of the OHSU Knight Cancer Institute’s Melanoma Research Program and chair of the Department of Dermatology in the OHSU School of Medicine, co-authored a Nature News and Views perspective that heralded artificial intelligence, or AI, an important step in the “final frontier” in cancer diagnosis.

Suse Skinner, 70, is fighting her second battle with cancer. In 2005 she was diagnosed with breast cancer, then in August 2016 she was admitted to OHSU for her first induction chemotherapy session for acute myeloid leukemia, where she underwent 24/7 chemotherapy for six days followed by six weeks of recovery.

An OHSU and Oregon State University study finds aspirin may slow the spread of some types of colon and pancreatic cancer cells, Their findings are published in the American Journal of Physiology—Cell Physiology.

Conversations centered on health care are increasingly taking place on social media. For example, doctors, patients, advocates, the FDA and members of the pharmaceutical industry frequently interact on Twitter, discussing new drugs and devices.

Recognizing a critical need to improve national vaccination rates for human papillomavirus, or HPV, the OHSU Knight Cancer Institute has united with all 69 National Cancer Institute-designated cancer centers in issuing a joint statement in support of recently revised recommendations from the Centers for Disease Control and Prevention.

The OHSU Knight Cancer Institute has announced grant funding to 10 community-led projects around the state in the latest funding cycle for its Community Partnership Program.

OHSU Knight Cancer Institute oncologist publishes New England Journal of Medicine “Perspective” on her experience treating a patient in rural Oregon with breast cancer and mental illness.

OHSU researcher Sudarshan Anand, Ph.D., has a contemporary analogy to describe microRNA: “I sometimes compare MicroRNA to tweets — they’re short, transient and constantly changing.”

OHSU research published in the Journal of Clinical Oncology shows that patients with lung cancer who have symptoms of depression have overall lower survival rates than those without depression symptoms.

As we age, as many as 10 to 30 percent of us spontaneously carry mutations in our blood cells that put us at risk for blood cancers and heart disease. Researchers at OHSU are leading a unique study for women aged 65 and older called WEAR, or Women.